The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day - PubMed (original) (raw)

Review

The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day

Dominick J Angiolillo. Drugs. 2012.

Abstract

Our knowledge of the mechanisms of platelet-mediated thrombosis has increased dramatically over the last 40 years. This increased understanding has identified treatment strategies for acute coronary syndromes (ACS) by targeting key mediators of platelet activation and aggregation processes. Aspirin (acetylsalicylic acid) monotherapy improves patient outcomes by irreversibly inhibiting the cyclooxygenase (COX)-1 enzyme in the arachidonic acid pathway. The later-developed thienopyridines, prodrugs that irreversibly inhibit the P2Y(12) receptor, and therefore adenosine diphosphate (ADP) binding, further enhance platelet inhibition and patient outcomes. The thienopyridine clopidogrel has been the standard of care, but it is limited by variable response and treatment failure. A more potent thienopyridine, prasugrel, requires fewer hepatic metabolic steps for activation, and elicits significantly improved outcomes for patients with ACS. The increased potency of prasugrel is associated with an increase in Thrombolysis in Myocardial Infarction (TIMI)-defined major bleeding compared with clopidogrel. Ticagrelor represents a new chemical class of agents called the cyclopentyltriazolopyrimidines. It interacts reversibly with the platelet P2Y(12) receptor, and does not require metabolic bioactivation for activity. Data show a significant improvement in ischaemic outcomes, including mortality, for ticagrelor compared with clopidogrel, without an increase in overall major bleeding, although non-coronary artery bypass graft bleeding is increased. Glycoprotein IIb/IIIa targeted agents (abciximab, tirofiban and eptifibatide) are also used in ACS patients undergoing percutaneous coronary interventions. These inhibitors utilize a different mechanism of action by preventing fibrinogen-mediated platelet aggregation. Other therapeutic strategies for platelet inhibition are being evaluated, including the investigative protease-activated receptor (PAR)-1 and thromboxane A(2) antagonists. This review highlights the mechanisms of action of these agents, and the continuing evolution of ACS therapy.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Am Coll Cardiol. 2007 Apr 10;49(14):1505-16 - PubMed
    1. N Engl J Med. 2001 Aug 16;345(7):494-502 - PubMed
    1. J Thromb Thrombolysis. 2012 Nov;34(4):499-505 - PubMed
    1. J Clin Pharmacol. 2010 Feb;50(2):126-42 - PubMed
    1. Thromb Haemost. 2010 Jan;103(1):213-23 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources